1. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development
   Davinder Singh et al, 2021, Journal of Controlled Release CrossRef
2. Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy
   Xin Yu Koh et al, 2022, Scientific Reports CrossRef
3. A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer
   Zhen Song et al, 2024, Scientific Reports CrossRef
4. RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells
   Jun‑Feng Chen et al, 2018, Oncology Letters CrossRef
5. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase
   Xin Yu Koh et al, 2019, Oncogene CrossRef
6. Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer
   Ziliang Wang et al, 2021, Cell Biology and Toxicology CrossRef
7. Tyrosine kinase receptor RON activates MAPK/RSK/CREB signal pathway to enhance CXCR4 expression and promote cell migration and invasion in bladder cancer
   Junfeng Chen et al, 2022, Aging CrossRef
8. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma
   Sun‑Ae Kim et al, 2019, International Journal of Oncology CrossRef